<DOC>
	<DOCNO>NCT00072683</DOCNO>
	<brief_summary>This study ’ purpose determine whether tolvaptan safely effectively return body ’ balance sodium water toward normal , characterize quantify potential clinical benefit treatment .</brief_summary>
	<brief_title>“ SALT Trial ” Study Ascending Levels Tolvaptan Hyponatremia</brief_title>
	<detailed_description>Hyponatremia define serum sodium concentration lower limit normal frequently encounter electrolyte abnormality hospitalize patient . Generally speaking , case hyponatremia mild . However , serum sodium fall 130 mEq/L , possibility significant morbidity mortality increase , clinician initiate corrective therapy serum sodium value approach 130 mEq/L low . The reason treat hyponatremia relate symptom , may quite disturb patient , well potential outcome include permanent neurological damage death . There also grow awareness association hyponatremia increase mortality patient heart failure.A common theme underlying occurrence hyponatremia whether set congestive heart failure , hepatic failure ascites , syndrome inappropriate anti-diuretic hormone ( SIADH ) non-osmotic secretion arginine vasopressin ( AVP ) . The presence excess AVP lead fluid retention hyponatremia . Agents antagonize AVP , cause proportionally water diuresis solute excretion , could offer significant treatment option patient hyponatremia , compare fluid restriction alone . Treatment hyponatremia , particularly clinical setting decompensated congestive heart failure , difficult conventional diuretic cause neurohormonal activation stimulate inappropriate release vasopressin , lead additional retention free water aggravation hypoosmolality . Similarly , cirrhosis ascites SIADH , conventional diuretic either minimally effective completely contraindicate . An alternative approach symptom relief treatment hyponatremia may use vasopressin antagonist , increase free water clearance proportionally less effect sodium excretion . Tolvaptan oral vasopressin antagonist relative affinity V2 receptor show induce diuresis proportionally free-water sodium loss . The current study undertaken order evaluate whether tolvaptan , oral AVP inhibitor , effective correct mild moderate hyponatremia , elucidate effect correction subject ’ well-being .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Water-Electrolyte Imbalance</mesh_term>
	<mesh_term>Water Intoxication</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Inclusion Criteria Hyponatremia euvolemic hypervolemic state , define serum sodium &lt; 135 mEq/L prior randomization . Able give Informed Consent Exclusion Criteria Women breast feeding female childbearing potential use acceptable contraceptive method Hyponatremia hypovolemic state . Acute transient hyponatremia associate head trauma postoperative state . Hyponatremia due uncontrolled hypothyroidism uncontrolled adrenal insufficiency . Cardiac surgery within 30 day potential study enrollment , exclude percutaneous coronary intervention . History myocardial infarction within 30 day potential study enrollment . History sustain ventricular tachycardia ventricular fibrillation within 30 day , unless presence automatic implantable cardioverter defibrillator . Severe angina include angina rest slight exertion and/or unstable angina . History cerebrovascular accident within last 30 day . 10 ) Subjects psychogenic polydipsia may include , however subject psychiatric illness may include . Systolic arterial blood pressure &lt; 90 mmHg . History hypersensitivity and/or idiosyncratic reaction benzazepine benzazepine derivative ( benazepril ) . History drug medication abuse within past year , current alcohol abuse . Uncontrolled diabetes mellitus define fast glucose &gt; 300mg/dL . Urinary tract obstruction except BPH nonobstructive . Previous participation another clinical drug trial within past 30 day . Previous participation tolvaptan clinical trial . Terminally ill moribund condition little chance short term survival . Serum creatinine &gt; 3.5 mg/dL . Serum sodium &lt; 120 mEq/L associate neurologic impairment , i.e . symptom apathy , confusion , seizure . Patients progressive episodic neurologic disease multiple sclerosis history multiple stroke . ChildPugh score great 10 ( unless approve ) Patients receive intravenous fluid rate great KVO ( Keep Vein Open ) . Hyponatremia due lab artifacts Patients receive AVP analog treatment condition . Patients receive within 7 day randomization , medication treatment hyponatremia specifically : demeclocycline , lithium carbonate urea Patients likely require IV saline correction symptomatic asymptomatic severe hyponatremia course study . Severe pulmonary artery hypertension Hyponatremia result medication safely withdrawn</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Sodium</keyword>
	<keyword>SIADH</keyword>
	<keyword>Vasopressin</keyword>
	<keyword>CHF</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>salt</keyword>
	<keyword>water</keyword>
	<keyword>electrolyte</keyword>
</DOC>